Compare XBIT & CULP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | CULP |
|---|---|---|
| Founded | 2005 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Textiles |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 46.2M |
| IPO Year | 2015 | 1994 |
| Metric | XBIT | CULP |
|---|---|---|
| Price | $1.95 | $3.47 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 82.6K | 40.9K |
| Earning Date | 11-12-2026 | 12-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.06 |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | ★ $203,482,000.00 |
| Revenue This Year | N/A | $3.15 |
| Revenue Next Year | $30.47 | $1.77 |
| P/E Ratio | ★ N/A | $7.47 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.80 | $2.70 |
| 52 Week High | $2.73 | $4.17 |
| Indicator | XBIT | CULP |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 43.36 |
| Support Level | $1.83 | $3.46 |
| Resistance Level | $2.42 | $3.48 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 45.45 | 37.41 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Culp Inc manufactures, sources, and markets mattress fabrics, sewn covers for mattresses, foundations, and other bedding products, and upholstery fabrics, including cut and sewn kits, for residential, commercial, and hospitality furniture and other applications. It markets fabrics produced at its manufacturing facilities and fabrics sourced through other suppliers to bedding and furniture companies. Its products serve the bedding, residential furnishings, commercial furnishings, and hospitality furnishings markets. Its segments are: Bedding and Upholstery, with Bedding generating the maximum revenue. The Bedding segment supplies the bedding market, comprising mattress sets and bedding accessory products. It generates the maximum revenue from the United States.